<DOC>
	<DOCNO>NCT01767623</DOCNO>
	<brief_summary>This open-label , Phase I study evaluate impact severe hepatic impairment pharmacokinetics safety vemurafenib patient BRAF V600 mutation positive cancer . Patients receive vemurafenib 960 mg ( normal hepatic function ) 720 mg ( severe hepatic impairment ) orally twice daily Days 1 20 ( morning dose ) Day 27 onwards disease progression inacceptable toxicity occur .</brief_summary>
	<brief_title>A Study The Impact Severe Hepatic Impairment Pharmacokinetics Safety Vemurafenib BRAF V600 Mutation-Positive Cancer Patients</brief_title>
	<detailed_description />
	<criteria>Adult patient , &gt; /= 18 year age Histologically confirm BRAF V600 mutationpositive advance solid malignancy metastatic unresectable standard curative palliative measure exist longer effective Normal impair hepatic function ( hepatic function classify accord NCI Organ Dysfunction Working Group criterion ) For patient hepatic impairment : Stable hepatic function least 2 week Day 1 Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /=2 Patients history recent brain metastasis must complete radiation therapy least 4 week Day 1 , without intervene sign brain lesion progression require steroid start protocol ( Day 1 ) . Patients gliomas know brain metastasis require anticonvulsant must seizure free 1 month prior enrollment Life expectancy &gt; 8 week Adequate hematologic renal function Females patient childbearing potential male patient female partner childbearing potential must agree use two adequate method contraception define protocol course study least 6 month completion study treatment Allergy hypersensitivity component vemurafenib formulation Requirement immediate urgent treatment vemurafenib intermittent schedule vemurafenib employed Days 126 trial clinically acceptable Chemotherapy , biologic therapy , immunotherapy , radiotherapy within 4 week prior enter study , recover AEs agent administer 4 week earlier Gliomas know brain metastasis require corticosteroid History clinically significant cardiac pulmonary dysfunction HIVpositive patient require antiviral treatment include protease inhibitor Active infection chronic infection require chronic suppressive antibiotic Pregnancy breastfeed Day 1 History malabsorption clinically significant metabolic dysfunction Active autoimmune disease Current , recent ( within 28 day prior Day 1 ) , plan use investigational product outside study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>